[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

UA84432C2 - Очищенные пептиды и соединения, которые их содержат - Google Patents

Очищенные пептиды и соединения, которые их содержат

Info

Publication number
UA84432C2
UA84432C2 UAA200601920A UAA200601920A UA84432C2 UA 84432 C2 UA84432 C2 UA 84432C2 UA A200601920 A UAA200601920 A UA A200601920A UA A200601920 A UAA200601920 A UA A200601920A UA 84432 C2 UA84432 C2 UA 84432C2
Authority
UA
Ukraine
Prior art keywords
compounds containing
purified peptides
contrast agents
peptides
peptide
Prior art date
Application number
UAA200601920A
Other languages
English (en)
Ukrainian (uk)
Inventor
Жаода Жанг
Питер Д. Караван
Томас Дж. Макмурри
Эндрю Колодзей
Шрикумар Наир
Джон С. Амедио
Стефан Дюма
Ксифанг Ванг
Веи-Чуан Сан
Александр Л. Ниворожкин
Штеффи К. Коэрнер
Original Assignee
Эпикс Медикал, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эпикс Медикал, Инк. filed Critical Эпикс Медикал, Инк.
Publication of UA84432C2 publication Critical patent/UA84432C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0039—Coumarin dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/122—Macromolecular compounds dimers of complexes or complex-forming compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/12—Macromolecular compounds
    • A61K49/124—Macromolecular compounds dendrimers, dendrons, hyperbranched compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Объектами данного изобретения являются очищенные пептиды и соединения, которые их содержат, которые способны образовывать дисульфидную связь при отсутствии условий для восстановления и имеют специфическую связную родственность к фибрину.
UAA200601920A 2001-07-30 2002-07-30 Очищенные пептиды и соединения, которые их содержат UA84432C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30872101P 2001-07-30 2001-07-30
UA2004010709A UA81226C2 (en) 2001-07-30 2002-07-30 Peptide-based multimeric targeted contrast agents

Publications (1)

Publication Number Publication Date
UA84432C2 true UA84432C2 (ru) 2008-10-27

Family

ID=23195121

Family Applications (2)

Application Number Title Priority Date Filing Date
UA2004010709A UA81226C2 (en) 2001-07-30 2002-07-30 Peptide-based multimeric targeted contrast agents
UAA200601920A UA84432C2 (ru) 2001-07-30 2002-07-30 Очищенные пептиды и соединения, которые их содержат

Family Applications Before (1)

Application Number Title Priority Date Filing Date
UA2004010709A UA81226C2 (en) 2001-07-30 2002-07-30 Peptide-based multimeric targeted contrast agents

Country Status (23)

Country Link
US (5) US6991775B2 (ru)
EP (1) EP1420681B1 (ru)
JP (2) JP4298501B2 (ru)
KR (2) KR20040020074A (ru)
CN (1) CN1599577A (ru)
AR (1) AR036196A1 (ru)
AU (1) AU2002318931B2 (ru)
BR (1) BR0211623A (ru)
CA (1) CA2455638C (ru)
CO (1) CO5560528A2 (ru)
EA (1) EA006239B1 (ru)
EC (1) ECSP044996A (ru)
HU (1) HUP0402029A3 (ru)
IL (1) IL160001A0 (ru)
MX (1) MXPA04000967A (ru)
NO (1) NO20040402L (ru)
NZ (1) NZ531338A (ru)
PL (1) PL368807A1 (ru)
TW (2) TWI284539B (ru)
UA (2) UA81226C2 (ru)
WO (1) WO2003011115A2 (ru)
YU (1) YU9404A (ru)
ZA (1) ZA200401606B (ru)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284539B (en) * 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide
CA2461836A1 (en) * 2001-10-16 2003-04-24 Epix Medical, Inc. Detection and treatment of intravascular lesions
AR047692A1 (es) * 2003-07-10 2006-02-08 Epix Medical Inc Imagenes de blancos estacionarios
JP2008508333A (ja) * 2004-08-05 2008-03-21 ヨハン ウォルフガング ゲーテ−ウニベルジテート フランクフルト アム マイン 標的分子の改変および組織化のための多価キレーター
DE102004038134B4 (de) 2004-08-05 2013-07-25 Johann Wolfgang Goethe-Universität Frankfurt am Main Multivalente Chelatoren zum Modifizieren und Organisieren von Zielmolekülen, Verfahren zu ihrer Herstellung sowie ihre Verwendung
US20060275217A1 (en) * 2005-05-06 2006-12-07 Caravan Peter D Chemical exchange saturation transfer contrast agents
JP4559922B2 (ja) * 2005-06-21 2010-10-13 株式会社東芝 蛍光性錯体及びそれを用いた照明装置
CA2614486C (en) 2005-07-13 2014-09-16 Georgia State University Research Foundation, Inc. Contrast agent comprising a scaffold protein and a metal ion chelating site integrated therein
KR100703593B1 (ko) * 2005-08-08 2007-04-06 경북대학교 산학협력단 Ｄｔｐａ-비스（피콜린아미드）리간드，이를 포함하는가돌리늄 착물 및 이들의 제조 방법
EP1928507B1 (en) * 2005-09-09 2015-11-11 Georgia State University Research Foundation, Inc. Targeted contrast agents and methods for targeting contrast agents
JP5377965B2 (ja) * 2005-09-09 2013-12-25 ジョージア ステート ユニバーシティ リサーチ ファウンデーション、インコーポレイテッド 標的化された造影剤および造影剤を標的化するための方法
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
JP5368099B2 (ja) 2005-10-07 2013-12-18 ゲルベ ガリウムと錯体形成することが可能なシグナル部分にカップリングされた、生物学的標的の認識のための部分を含んでなる化合物
EP1933884B1 (en) * 2005-10-11 2017-09-06 Huntington Medical Research Institutes Imaging agents and methods of use thereof
JP2009513681A (ja) 2005-10-28 2009-04-02 インヴィトロジェン コーポレーション キナーゼおよびユビキネーションアッセイ法
FI20055653A (fi) 2005-12-08 2007-06-09 Wallac Oy Leimausreagenssi
WO2007073792A1 (de) * 2005-12-19 2007-07-05 Bayer Schering Pharma Aktiengesellschaft Verfahren zur herstellung von 4,4-diphenylcyclohexanol
US20080058636A1 (en) * 2005-12-29 2008-03-06 Epix Pharmaceuticals, Inc. Methods of myocardial imaging
EP2054514A4 (en) 2006-08-04 2009-11-04 Univ Georgia State Res Found ENZYME SENSORS, METHODS OF PREPARATION AND USE OF SUCH SENSORS, AND METHODS OF DETECTING PROTEASE ACTIVITY
EP2097507B1 (en) 2006-12-14 2015-05-06 Georgia State University Research Foundation, Inc. Analyte sensors and use thereof for detecting analyte activity
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
FR2914304B1 (fr) 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2914303A1 (fr) 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
BRPI0907612A2 (pt) 2008-01-08 2015-07-21 Lantheus Medical Imaging Inc Conjugados de n-coxiamida como agentes de imageamento
US20090208421A1 (en) 2008-02-19 2009-08-20 Dominique Meyer Process for preparing a pharmaceutical formulation of contrast agents
US20090236541A1 (en) * 2008-03-24 2009-09-24 General Electric Company System and Methods for Optical Imaging
EP3498307A1 (en) 2008-04-02 2019-06-19 Georgia State University Research Foundation, Inc. Contrast agents, methods for preparing contrast agents, and methods of imaging
WO2010016938A2 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Glucose-dependent insulinotropic polypeptide analogues
AU2009280021B2 (en) * 2008-08-07 2012-10-04 Ipsen Pharma S.A.S. Analogues of glucose-dependent insulinotropic polypeptide (GIP) modified at N-terminal
CN104829706A (zh) * 2008-08-07 2015-08-12 益普生制药股份有限公司 糖依赖性胰岛素释放肽的类似物
PT2320923E (pt) * 2008-08-07 2015-02-24 Ipsen Pharma Sas Análogos truncados de polipéptido insulinotrópico dependente de glucose
US8889635B2 (en) 2008-09-30 2014-11-18 The Regents Of The University Of Michigan Dendrimer conjugates
WO2010054321A2 (en) 2008-11-07 2010-05-14 The Regents Of The University Of Michigan Methods of treating autoimmune disorders and/or inflammatory disorders
US8864821B2 (en) * 2008-11-26 2014-10-21 Visen Medical, Inc. Methods and compositions for identifying subjects at risk of developing stent thrombosis
FR2942227B1 (fr) 2009-02-13 2011-04-15 Guerbet Sa Utilisation de tampons pour la complexation de radionucleides
WO2010121133A2 (en) 2009-04-17 2010-10-21 The General Hospital Corporation Multimodal imaging of fibrin
BRPI1009900A2 (pt) 2009-03-19 2016-03-15 Wyeth Llc métodos para a preparação de ácido [2-(8,9-dioxo-2,6-diazabiciclo[5.2.0]non-1(7)-en-2-il)etil]fosfônico e seus precursores
US8877157B2 (en) 2009-07-08 2014-11-04 Lantheus Medical Imaging, Inc. N-alkoxyamide conjugates as imaging agents
WO2011005609A2 (en) * 2009-07-08 2011-01-13 Mayo Foundation For Medical Education And Research Imaging gastrointestinal volumes and motility
WO2011059609A2 (en) 2009-10-13 2011-05-19 The Regents Of The University Of Michigan Dendrimer compositions and methods of synthesis
WO2011059586A2 (en) 2009-10-30 2011-05-19 The Regents Of The University Of Michigan Multifunctional small molecules
WO2011152782A1 (en) * 2010-06-01 2011-12-08 Ge Healthcare Bio-Sciences Ab Novel chelator and use thereof
FR2968562B1 (fr) 2010-12-14 2013-01-11 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de muc5ac
FR2968999B1 (fr) 2010-12-20 2013-01-04 Guerbet Sa Nanoemulsion de chelate pour irm
US9011816B2 (en) * 2011-03-25 2015-04-21 Case Western Reserve University Fibronectin targeting contrast agent
FR2980364B1 (fr) 2011-09-26 2018-08-31 Guerbet Nanoemulsions et leur utilisation comme agents de contraste
US9402911B2 (en) 2011-12-08 2016-08-02 The Regents Of The University Of Michigan Multifunctional small molecules
FR3001154B1 (fr) 2013-01-23 2015-06-26 Guerbet Sa Magneto-emulsion vectorisee
US9849201B2 (en) 2013-05-03 2017-12-26 Washington University Homing agents
WO2014210546A1 (en) 2013-06-27 2014-12-31 University Of Washington Through Its Center For Commercialization Biocompatible polymeric system for targeted treatment of thrombotic and hemostatic disorders
WO2015017815A1 (en) 2013-08-01 2015-02-05 Rochester Institute Of Technology Modular imaging agents containing amino acids and peptides
WO2015038968A1 (en) 2013-09-13 2015-03-19 The General Hospital Corporation Activatable fibrin-binding probes
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
US10471162B2 (en) 2014-06-20 2019-11-12 The General Hospital Corporation Collagen targeted imaging probes
EP3294316A4 (en) * 2015-05-06 2018-10-17 H. Lee Moffitt Cancer Center And Research Institute, Inc. Radiotherapeutic and companion imaging agents to target mc1r
EP3101012A1 (en) 2015-06-04 2016-12-07 Bayer Pharma Aktiengesellschaft New gadolinium chelate compounds for use in magnetic resonance imaging
WO2017004211A1 (en) 2015-06-29 2017-01-05 Collagen Medical, LLC Collagen imaging compositions
CN114890941A (zh) 2015-08-13 2022-08-12 通用医疗公司 用于mr分子成像的基于锰的螯合缀合物
US10975060B2 (en) 2016-11-28 2021-04-13 Bayer Pharma Aktiengesellschaft High relaxivity gadolinium chelate compounds for use in magnetic resonance imaging
CN106946926A (zh) * 2017-02-27 2017-07-14 西北大学 一种具有多齿氨羧类二聚体螯合剂及其制备方法、应用和分离介质
CN110891614A (zh) 2017-05-05 2020-03-17 融合制药公司 Igf-1r单克隆抗体及其用途
CA3062553C (en) 2017-05-05 2024-02-06 Fusion Pharmaceuticals Inc. Pharmacokinetic enhancements of bifunctional chelates and uses thereof
US10093741B1 (en) 2017-05-05 2018-10-09 Fusion Pharmaceuticals Inc. IGF-1R monoclonal antibodies and uses thereof
RU2681318C1 (ru) * 2017-11-24 2019-03-06 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ получения иммуносупрессорного пептида Abu-TGIRIS-Abu, меченного ионом Gd3+
WO2020007822A1 (en) 2018-07-02 2020-01-09 Conservatoire National Des Arts Et Metiers (Cnam) Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof
JP7520007B2 (ja) 2018-11-23 2024-07-22 バイエル アクチェンゲゼルシャフト 造影剤の製剤およびその調製方法
CN111233714B (zh) * 2020-03-18 2022-04-08 滨海吉尔多肽有限公司 一种maps多肽的制备方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4622420A (en) 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4897255A (en) 1985-01-14 1990-01-30 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US4880008A (en) 1985-05-08 1989-11-14 The General Hospital Corporation Vivo enhancement of NMR relaxivity
US4678667A (en) 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5001230A (en) 1988-02-18 1991-03-19 Schering Corporation T cell activation markers
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB9111199D0 (en) 1991-05-23 1991-07-17 Sandoz Ltd Improvements in or relating to organic compounds
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5641878A (en) 1991-05-15 1997-06-24 Diatron Corporation Porphyrin, azaporphyrin, and related fluorescent dyes free of aggregation and serum binding
US5009069A (en) * 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
CA2104860A1 (en) * 1991-03-08 1992-09-09 Thomas T. Andersen Endothelin antagonists
WO1993017719A1 (en) 1992-03-13 1993-09-16 Diatech, Inc. TECHNETIUM-99m LABELED PEPTIDES FOR IMAGING INFLAMMATION
US5637759A (en) 1992-07-30 1997-06-10 The Regents Of The University Of California Metal-ligating amino acid derivatives for MRI and for peptide synthesis
US5705143A (en) * 1994-01-12 1998-01-06 Amersham International Plc Biological targeting agents
CA2193508A1 (en) 1994-07-11 1996-01-25 Eugene D. Thorsett Inhibitors of leukocyte adhesion
US6001809A (en) * 1994-07-11 1999-12-14 Elan Pharmaceuticals, Inc. Inhibitors of leukocyte adhesion
TW319763B (ru) 1995-02-01 1997-11-11 Epix Medical Inc
GB9502065D0 (en) 1995-02-02 1995-03-22 Nycomed Imaging As Contrast media
WO1996036361A1 (en) 1995-05-18 1996-11-21 The Regents Of The University Of Michigan Dna binding antibodies
US5891418A (en) * 1995-06-07 1999-04-06 Rhomed Incorporated Peptide-metal ion pharmaceutical constructs and applications
DE19539409C2 (de) 1995-10-11 1999-02-18 Diagnostikforschung Inst Kontrastmittel für die Nahinfrarot-Diagnostik
AU7299796A (en) 1995-10-17 1997-05-07 Rohn Enzyme Finland Oy Cellulases, the genes encoding them and uses thereof
DE69829891T2 (de) 1997-04-07 2005-10-06 Genentech, Inc., South San Francisco Anti-VEGF Antikörper
IT1291623B1 (it) * 1997-04-18 1999-01-11 Bracco Spa Procedimento per la coniugazione di chelanti con molecole contenenti gruppi amminici
US6342598B1 (en) 1998-11-26 2002-01-29 Bracco International B.V. Amphipatic polycarboxylic chelates and complexes with paramagnetic metals as MRI contrast agents
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
AU768859B2 (en) * 1999-07-29 2004-01-08 Dyax Corp. Binding moieties for fibrin
MXPA02001017A (es) 1999-07-29 2002-08-12 Epix Medical Inc Agente multimerico de formacion de imagenes con especificidad hacia el blanco mediante su union a multiples regiones.
JP2003528035A (ja) 1999-10-01 2003-09-24 アングストロム ファーマシューティカルズ， インコーポレイテッド ｕＰＡおよびｕＰＡＲを標的化する診断プロ−ブおよび治療薬
WO2001030398A2 (en) 1999-10-22 2001-05-03 Insight Neuroimaging Systems, Llc Ligand chelated paramagnetic mri contrast agents
WO2001052906A2 (en) * 2000-01-22 2001-07-26 Epix Medical, Inc. Magnetic resonance imaging using contrast agents prodrugs bioactivated by enzymatic cleavage
US6656448B1 (en) * 2000-02-15 2003-12-02 Bristol-Myers Squibb Pharma Company Matrix metalloproteinase inhibitors
US6517814B2 (en) * 2001-01-09 2003-02-11 Bristol-Myers Squibb Pharma Company Macrocyclic chelants useful for metallopharmaceuticals
TWI284539B (en) * 2001-07-30 2007-08-01 Epix Pharm Inc A method for making a magnetic resonance (MR) imaging agent, a MR imaging contrast agent, a method for altering stability of a peptide and a modified peptide

Also Published As

Publication number Publication date
TWI284539B (en) 2007-08-01
US20030180222A1 (en) 2003-09-25
US7927581B2 (en) 2011-04-19
EA006239B1 (ru) 2005-10-27
BR0211623A (pt) 2004-07-13
YU9404A (sh) 2006-08-17
TWI240632B (en) 2005-10-01
ZA200401606B (en) 2005-05-03
US20060039861A1 (en) 2006-02-23
CA2455638C (en) 2013-01-22
US20030216320A1 (en) 2003-11-20
CN1599577A (zh) 2005-03-23
KR20040020074A (ko) 2004-03-06
NZ531338A (en) 2005-08-26
US6991775B2 (en) 2006-01-31
MXPA04000967A (es) 2005-02-17
HUP0402029A3 (en) 2010-01-28
AU2002318931B2 (en) 2008-01-17
CA2455638A1 (en) 2003-02-13
JP2005314438A (ja) 2005-11-10
ECSP044996A (es) 2004-06-28
JP2004536875A (ja) 2004-12-09
HUP0402029A2 (hu) 2005-01-28
WO2003011115A2 (en) 2003-02-13
EP1420681A4 (en) 2009-08-05
JP4298501B2 (ja) 2009-07-22
KR20080100856A (ko) 2008-11-19
US7238341B2 (en) 2007-07-03
TW200512006A (en) 2005-04-01
EA200400241A1 (ru) 2004-06-24
NO20040402L (no) 2004-03-25
US20050074411A1 (en) 2005-04-07
AR036196A1 (es) 2004-08-18
UA81226C2 (en) 2007-12-25
EP1420681A2 (en) 2004-05-26
EP1420681B1 (en) 2013-12-25
PL368807A1 (en) 2005-04-04
IL160001A0 (en) 2004-06-20
CO5560528A2 (es) 2005-09-30
US20070185311A1 (en) 2007-08-09
WO2003011115A3 (en) 2003-05-22

Similar Documents

Publication Publication Date Title
UA84432C2 (ru) Очищенные пептиды и соединения, которые их содержат
MXPA04003333A (es) Remodelado y glicoconjugacion de peptidos.
WO2002070992A8 (en) Ambulatory navigation system
DE60235761D1 (de) Isoform des vegfs
DE60141546D1 (de) Polypeptide enthaltend extrazellulären Domäne von IL-20RA und/oderr IL-20RB
AU2003275075A1 (en) Compstatin analogs with improved activity
WO2002044215A3 (en) Hybrid antibodies
AU2002217010A1 (en) Peptides, the production and use thereof for binding immunoglobulins
AUPP589598A0 (en) Novel peptides
HK1093308A1 (en) Use of peptides derived from the b beta chain of human fibrinogen for the treatment of shock
MXPA05008080A (es) Inhibidores peptidicos de toxinas derivadas de la ll-37.
ATE242630T1 (de) Beladene bakterienghosts als träger- und targetingvehikel
WO2002100895A3 (de) Antimikrobiell wirkendes peptid
AU7216498A (en) Inhibitors of the urokinase receptor
EP1265073A3 (en) Methods for determining plasma free drug concentration
ATE385805T1 (de) Neue peptide
EP2305311A3 (en) Glycoconjugation of peptides
WO2001083518A3 (en) Molecules that modulate ubiquitin-dependent proteolysis and methods for identifying same
IL193310A0 (en) Antibody directed against a polypeptide that interacts with parkin and pharmaceutical compositions comprising the same
HK1082510A1 (en) Promoter to il-18bp, its preparation and use
WO2002014346A8 (en) Antimicrobial peptides isolated from fish
AU5155699A (en) Peptides for inhibiting hpv e7 proteins
WO2002031127A3 (en) Cloning and recombinant expression of mammalian group xii secreted phospholipase a¿2?
TWI255718B (en) Ameliorative agent for low vasopressin concentration
WO2003084987A3 (en) Polypeptides from bacteria and uses thereof